Omeprazole

證據等級: L5

預測適應症: 2 個

One-Sentence Summary

Omeprazole is a proton pump inhibitor (PPI) established for acid-related gastrointestinal conditions such as peptic ulcer disease, GERD, and H. pylori eradication. The TxGNN model predicts it may be effective for Duodenogastric Reflux, with 1 clinical trial and 20 publications currently identified in relation to this direction — though the evidence is mixed, with some studies also raising a carcinogenesis safety signal (see below).

Quick Overview

Item	Content
Original Indication	Not documented in German regulatory data (drug not marketed in Germany). Per established PPI pharmacology and supporting literature in this pack (e.g., PMID 18679668), omeprazole is used for peptic ulcer disease, H. pylori infection, GERD, NSAID-induced GI lesions, and Zollinger-Ellison syndrome
Predicted New Indication	Duodenogastric Reflux
TxGNN Prediction Score	99.64%
Evidence Level	L3 (observational/clinical studies, no completed RCTs specific to this indication)
Germany Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available (DrugBank MOA field is a data gap). Based on known pharmacology, omeprazole is a proton pump inhibitor that irreversibly blocks the H+/K+-ATPase in gastric parietal cells, suppressing acid secretion — a mechanism proven effective across peptic ulcer disease, GERD, and H. pylori-related conditions.

Duodenogastric reflux (DGR) involves retrograde flow of duodenal contents (bile, pancreatic enzymes) into the stomach, often co-occurring with acid-related GI disorders and contributing to mucosal injury in conditions like Barrett's esophagus. Several clinical studies in this evidence pack (e.g., PMID 9824338, 10994616, 19491829) directly examined omeprazole's effect on DGR/DGOR in reflux populations, providing a plausible mechanistic bridge from the original acid-suppression indication to this new target.

However, the mechanistic picture is not uniformly favorable: multiple animal studies (PMID 10389684, 8943968, 33027361, 15052437) report that gastric acid blockade with omeprazole (and other PPIs) may potentiate mucosal growth stimulation and gastric carcinogenesis when combined with DGR, since higher intragastric pH can increase bile cytotoxicity. This nuance should be weighed carefully rather than treated as a straightforward "efficacy" signal.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT02685150	NA	Completed	157	Evaluated endoscopic Tri-Modal Imaging (NBI/AFI/WLI) to distinguish functional dyspepsia from acid/bile reflux disease; not a treatment-efficacy trial for omeprazole itself

Literature Evidence

PMID	Year	Type	Journal	Key Findings
9824338	1998	Clinical study	Gut	Omeprazole 20mg BID effect on duodenogastric and duodenogastro-oesophageal bile reflux in Barrett's oesophagus
10994616	2000	Clinical study	Scand J Gastroenterol	Effect of omeprazole on antral duodenogastric reflux in Barrett oesophagus
19491829	2009	Clinical study	Am J Gastroenterol	Compared degree of DGER/acid reflux between PPI responders and non-responders
16641575	2006	Clinical (prospective)	J Pediatr Gastroenterol Nutr	Prospective study of omeprazole for oesophageal bile reflux in children
12836018	2003	Case series	Eur J Pediatr	Description of primary duodenogastric reflux in children/adolescents
18679668	2008	Review	Eur J Clin Pharmacol	Review of PPI clinical use and pharmacokinetics (contextualizes original indications)
33027361	2020	Preclinical (rat)	Acta Cir Bras	Investigated whether omeprazole is protective against gastric adenocarcinoma under induced DGR
10389684	1999	Preclinical (rat)	Dig Dis Sci	⚠️ Gastric acid blockade with omeprazole promoted gastric carcinogenesis induced by DGR
8943968	1996	Preclinical (rat)	Dig Dis Sci	⚠️ DGR-induced foregut mucosal growth stimulation potentiated by gastric acid blockade (omeprazole arm)
15052437	2004	Preclinical (rat)	Gastric Cancer	⚠️ Related PPI (lansoprazole) promoted gastric carcinogenesis in rats with DGR — class-effect caution

Germany Market Information

Omeprazole currently has no marketing authorization records in the German regulatory dataset provided (0 licenses, market status: Not Marketed).

Safety Considerations

Please refer to the package insert for safety information.

Important caveat: The evidence pack flags a Blocking data gap (DG001) — TFDA/regulatory label warnings and contraindications have not yet been retrieved — which by definition prevents this candidate from entering the S1 safety pre-assessment stage. Additionally, DrugBank DDI query returned no results (query_status: not_found), so no drug interaction data could be evaluated at this time.

Conclusion and Next Steps

Decision: Hold

Rationale: While duodenogastric reflux shows plausible mechanistic rationale and moderate (L3) observational clinical evidence, a Blocking-severity data gap on regulatory safety labeling (warnings/contraindications) prevents completion of the mandatory S1 safety screen. This is compounded by a notable safety signal in preclinical literature suggesting acid suppression may potentiate gastric carcinogenesis in the presence of chronic DGR — a risk that must be resolved before advancing.

To proceed, the following is needed:

Retrieve TFDA (or equivalent) product label for warnings/contraindications (DG001, Blocking)
Retrieve DrugBank MOA data to support formal mechanistic-link scoring (DG002, High)
Complete a DDI database query (current status: not found)
Formally reconcile the conflicting evidence base — clinical studies suggesting symptomatic benefit vs. animal studies suggesting a long-term carcinogenesis risk under chronic acid suppression with DGR
Note: the secondary predicted indication (duodenal obstruction, rank 2) was already internally scored as L4/S0/Hold in this evidence pack, consistent with the overall conservative recommendation for this candidate
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.